Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals demonstrates a robust financial outlook, highlighted by a strong 4Q performance with U.S. sales growth of 36% that surpasses total prescription growth of 25%, suggesting a successful market strategy with its flagship product Eylea HD. The company's flagship Dupixent continues to show broad-based adoption across all approved indications, with projections indicating a significant revenue milestone exceeding $2 billion in eosinophilic esophagitis alone, further bolstered by anticipated growth in neurology and respiratory markets. Additionally, the anticipated escalation of collaboration profits due to a developmental balance reimbursement with Sanofi and the promising outcomes of ongoing and future product launches within oncology and other therapeutic areas position Regeneron as a leading player with substantial future revenue potential.

Regeneron Pharmaceuticals is facing a challenging financial landscape, with anticipated declines in quarterly sales consistent with recent trends, compounded by significant headwinds for the EYLEA franchise due to biosimilar competition, leading to a reduced forecast for EYLEA sales by nearly half. While worldwide fiscal year 2026 sales are projected to exceed $21 billion, the diminishing impact of EYLEA on the company's financial narrative is concerning, particularly in light of adjustments to collaboration revenue expectations stemming from Dupixent's label expansion. Key risks that could impede Regeneron's performance include rapid erosion of EYLEA sales, emerging competition for Dupixent, potential clinical setbacks in the development pipeline, and slower-than-expected sales growth across principal products.